Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SHR-1819 in chronic spontaneous urticaria
CTR20250324Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1819 in chronic idiopathic urticaria (CIU), sponsored by Hengrui Therapeutics. Started Mar 2025; status: completed.
02
Drugs
SHR-1819
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20250324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250324.